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WTO TRIPS and its effect on the supply and development of
medicines in China
A recent conference at the University of Hong Kong just
prior to the December 2005 World Trade Organization
(WTO) talks renewed attention on the WTO’s Agreement
on Trade-Related Aspects of Intellectual Property Rights
(TRIPS), in particular in relation to China. Here we provide
an introduction to TRIPS, discuss compulsory licensing, and
take two angles to view how TRIPS affects the supply and
development of medicines in China. We look at both recent
positive developments in the Chinese pharmaceutical
and biotechnology industry, and also at how TRIPS can
hamper the supply of medicines using HIV treatment as an
example.
Introduction to TRIPS
As ideas and knowledge gain prominence in global trade,
intellectual property (IP) rights are becoming increasingly
important. During the 1986-1994 Uruguay Round, the WTO
negotiated the Agreement on TRIPS to provide an initial
framework for IP regulation. Five broad issues were
addressed within the original agreement in an attempt to
bring IP protection under common international rules1:
1. How basic principles of global trade and other interna-
tional IP agreements should be applied;
2. How to adequately protect IP rights;
3. How countries should enforce those rights within their
own territories;
4. How to settle IP disputes between WTO members; and
5. Transitional arrangements to apply while the new
system is implemented.
Compulsory licensing
Most relevant to the medical profession are TRIPS’ effects
on patent protections. Patents usually apply for at least 20
years and are available for both products and processes,
although certain diagnostic, therapeutic, and surgical
methods cannot be protected by patents. One of the TRIPS
agreement’s major provisions is compulsory licensing: a
government may license the production of a patented
product or process without the consent of the patent
owner, provided the owner receives a reasonable royalty.
Compulsory licensing has existed since 1995 with the
provision that compulsory licenses be granted to mainly
supply domestic markets. The original agreement drew
criticism for what many saw as a failure to communicate
with the developing world. India, and to some extent China,
were exceptions because of their established pharmaceuti-
cal industries capable of manufacturing generic drugs.
Compulsory licensing was initially a major obstacle for
underdeveloped countries without the capability to produce
pharmaceuticals: how could they import pharmaceuticals
if the countries capable of manufacturing them were not
allowed to export?
A major revision was provided in the 2001 Doha
Ministerial Conference, which made it possible for
countries unable to manufacture pharmaceuticals to import
cheaper generic copies. All WTO members are allowed to
import under the compulsory license agreement, but most
developed countries have signed a waiver agreeing not to
do so. Hong Kong was one of a number of signatories on
a partial waiver stating that compulsory licensing would
only be used in a national emergency. A further amendment
within the Doha agreement allows least-developed coun-
tries (China is not classified as a least-developed country)
to delay protecting pharmaceutical patents until 2016.
How do TRIPS and compulsory licensing relate
to Hong Kong and China?
While Hong Kong is a founding member of the WTO,
the TRIPS agreement has had little local impact due to the
small size of the city’s pharmaceutical industry and the
relatively high purchasing power of Hong Kong residents.
China officially joined the WTO on 11 December 2001, but
had applied patent protections on medicine generally since
1993. Entrance into the WTO compelled China to enforce
IP protections, leading to a number of high-profile
litigation cases. In October 2003, Glaxosmithkline Limited
(GSK) blocked a number of Chinese drugmakers from
obtaining licenses for the type-2 diabetes treatment,
Avandia.2 It has been suggested that such actions are
driving innovation within the Chinese pharmaceutical
industry by shifting focus from generics manufacturing to
developing independently patented biotech drugs.2 Entrance
into the WTO may have catalysed the recent progress of
China’s biotechnology industry.
However, the enforcement of IP protections also raises
concerns regarding access to medicine. Médecins
sans Frontières (MSF) has highlighted the problems they
have confronted with the TRIPS agreement, particularly in
relation to HIV/AIDS treatment in China.3 In 2003, the
country had around 840 000 cases of HIV,4 and approxi-
mately 10% of those patients have AIDS. The Joint United
Nations Programme on HIV/AIDS (UNAIDS) has estimated
that China could have 10 million cases by 2010. China has
a number of major health care concerns—a crumbling
health system, poorly trained medical staff, too little
emphasis on adherence, lack of confidentiality, and stigma/
discrimination. Perhaps most critically, the cost of treatment
blocks access: approximately two thirds of the population
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has no health insurance, making the cost of treatment
prohibitive.
Recognising the threat of HIV, the Chinese Government
launched a national antiretroviral treatment (ART)
programme to provide free drugs to those most in need.5
When the scheme was first launched in 2003, first-line
treatment was the combination of stavudine (d4T) or
zidovudine (AZT) + didanosine (ddI) + nevirapine (NVP).5
All four drugs are locally produced and not patent-protected.
However, this combination is plagued by drug resistance,
as highlighted in recent reports revealing an alarming
62.7% rate of drug-resistant mutations in a group treated
for 6 months in Henan.6,7 Furthermore, this combination
has particularly strong side-effects and is potentially
dangerous for hepatitis B patients. All first-line WHO-
recommended HIV treatments now incorporate 3TC
(lamivudine), a drug patented by GSK that MSF reports
remains fairly inaccessible in China.8 3TC is a cheap and
effective component of HIV programmes in Africa, India,
Thailand, and elsewhere that is available as a generic at
US$65/year from the manufacturer Hetero. Critics asserted
that GSK was protecting 3TC’s other (lower-dose) use—
the treatment of hepatitis B—which is particularly wide-
spread in China.9,10 A recent report indicates that 80% of
patients currently receiving ART in China are on the older
treatment regimen excluding 3TC; no indication was
made of the number of patients (<20%) receiving a WHO-
mandated regimen that includes 3TC.5
In December 2004, GSK negotiated a supply deal with
China, and committed to donating 3TC for the next 5 years
in order to scale up ART in China.11 Officially, the first-line
treatment is now AZT + 3TC + NVP, with an annual
average cost of US$460 to US$480 per patient, supplied
free by the government to low-income patients under the
‘Four Frees and One Care’ policy.11 However, MSF reports
3TC is still not widely available in China’s national health
programme, making one of the developing world’s most
commonly used and effective fixed-dose combinations
(FDC)—3TC + d4T + NVP (taken as a single pill twice a
day)—also difficult to obtain.8 MSF has recently succeeded
in negotiating special authorisation to import FDC for use
in its own clinics, but beyond the MSF clinics, FDC remain
virtually unavailable and are not marketed legally anywhere
in China (personal communication). Access to formulations
for HIV-infected children also remains unavailable, and
alternative and second-line drugs, including lopinavir/
ritonavir (Kaletra), stavudine (Zerit) and tenofovir (TDF),
remain practically inaccessible.3
Furthermore, because China is considered a middle-
income developing country, tiered-pricing discounts are
not available despite the country’s massive population of
rural and urban poor. However, China does have a number
of generic producers, including Desano, MChem, North
East, and Zhejiang Huahai, capable of high-capacity
manufacturing to international standards. Indeed, these four
companies actually manufacture AZT, d4T, indinavir, ddI,
and NVP, both for the domestic market and for export.8
China has amended its patent law to allow production un-
der compulsory licensing, but to date no compulsory licenses
have been issued. HIV patients in China are left without
access to a number of patent-protected HIV drugs.
China’s domestic pharmaceutical industry
Most Chinese pharmaceutical companies produce generics,
but research into innovative drugs is rapidly expanding,
particularly in the biotechnology sector.12 In 2004 there were
an estimated 139 drugs in China’s pipeline (of approximately
700 in clinical development worldwide), although only 13
were in phase 3 trials.13 China’s drug development industry
has a number of advantages: a large patient population,
insight from traditional Chinese medicine,14 and lower costs
of labour and clinical trials. Furthermore, the approval
process has proved to be shorter in China compared with
the US, and Chinese trials can meet international standards.
This is a necessity for Chinese biotechnology companies,
as the Chinese market alone is often insufficient to fund
research and development costs, and drugs must meet
international standards to reach international markets. The
primary challenge of Chinese drug development industry is
raising venture capital.12 Foreign investors are particularly
concerned with monetary controls that do not allow capital
to leave China, but this situation is changing.
One particular success for the Chinese drug industry
was the first approval of a gene therapy for commercial
production. In early 2004, the Chinese biotechnology
company Shenzhen SiBono GenTech received approval
for Gendicine, a treatment for head and neck squamous
cell carcinoma. As of 31 July 2005, Gendicine had been
used to treat over 2600 patients.15
China must be considered both as a generics producer,
which is presently the major business of its pharmaceutical
industry, and also as a developer of innovative drugs
competing with the developed world. It is clear that over
the coming years, innovation rather than generics will
increasingly drive the Chinese pharmaceutical industry.
The WTO needs to facilitate access to medicine as
well as free trade
Both TRIPS and entrance into the WTO present opportuni-
ties and challenges for China’s health care system. Increased
competition from the international pharmaceutical industry
may be driving innovation in the Chinese biotechnology
sector, but it is also presenting problems with access to
medicine. Compulsory licensing mechanisms are in place
to domestically produce drugs needed by the Chinese
population. However, to date compulsory licensing has not
been used in China, perhaps through fear of trade or
diplomatic repercussions. Such restrictions on compulsory
licensing have recently been noted by the United Nations
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in relation to US trade policy.16 The WTO must take further
steps to ‘ringfence’ compulsory licensing in order to
effectively improve access to medicine in China and the
developing world.
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